Test: BRCA Deletion/Duplication Test  Date Reported: 12/11/2013

Result: Positive for BRCA1 Variant, Pathogenic

Results Summary:

<table>
<thead>
<tr>
<th>Gene</th>
<th>Variant Detected</th>
<th>Zygosity</th>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRCA1</td>
<td>Deletion of exon3</td>
<td>Heterozygous</td>
<td>Pathogenic</td>
</tr>
<tr>
<td>BRCA2</td>
<td>Not detected</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Interpretation:
A deletion of exon3 was identified, which was present in the heterozygous state. The variant detected in BRCA1 has been classified as associated with an increased risk for the Hereditary Breast and Ovarian Cancer Syndrome.

Recommendation:
Genetic counseling is strongly recommended to discuss the clinical implications of this result as well as recommendations for testing other family members. Genetic counselors are available for health care providers to discuss this result further at (800)345-GENE.

Comments:
Each gene sequence if interpreted independently of all other gene sequences. However, variants in different genes may sometimes interact to cause or modify a typically monogenic disease phenotype. It cannot be excluded that pathogenic variants were missed due to limitations inherent in the sequence analysis method used here (see Methods/Limitations section). In addition, the presence of the Hereditary Breast and Ovarian Cancer Syndrome due to a different genetic cause can also not be ruled out. Any interpretation given here should be clinically correlated with available information about presentation and relevant family history of the patient.

Methods/Limitations:
The multiple-ligation-probe amplification assay (MLPA) was performed to detect copy number variations (deletions and duplications) in the BRCA1 and BRCA2 genes.

References:

SAMPLE REPORT

LCLS Specimen Number: 123456789
  Patient Name: TEST, DELDUPPOS
    Date of Birth: 01/01/1975
    Gender: N
    Patient ID: 123456789

Account Number: 123456789
Ordering Physician: Dr. 101
Specimen Type: BLOOD
Date Collected: 12/10/2013
Date Received: 12/11/2013

Disclaimer:
Unless stated otherwise in this report, this test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. LabCorp is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing.

Alecia Willis, Ph.D., FACMG.
Ph.D., FACMG.

Testing performed by Laboratory Corporation of America Holdings, 1912 Alexander Drive, RTP, NC, 27709-0000  (800) 735-4087

Arundhati Chatterjee, MD
Medical Director
Val V. Zvereff, M.D., Ph.D., FACMG
National Director of Cytogenetics